Quarterly ResultMay 11, 2026, 08:02 AM
Heron Therapeutics Q1 Revenue $34.7M; Reaffirms 2026 Guidance
AI Summary
Heron Therapeutics announced its first quarter 2026 financial results, reporting total net revenue of $34.7 million, a 10.8% decrease year-over-year. The company's Acute Care franchise showed strong growth, with ZYNRELEF and APONVIE revenues increasing by 27% and 50% respectively. Despite a net loss of $8.1 million for the quarter, Heron reaffirmed its full-year 2026 guidance for net revenue of $173–$183 million and Adjusted EBITDA of $10–$20 million, citing recovery from early-quarter disruptions and ongoing commercial catalysts. The company also settled CINVANTI patent litigation with Baxter Healthcare.
Key Highlights
- Q1 2026 total net revenue was $34.7 million, down 10.8% year-over-year.
- Acute Care franchise net revenue grew 32% year-over-year to $13.6 million.
- ZYNRELEF net revenue increased 27% to $10.2 million; APONVIE net revenue rose 50% to $3.4 million.
- Oncology Supportive Care net revenue was $21.1 million, down 26.3% year-over-year.
- Q1 2026 net loss was $8.1 million, or $(0.04) per share.
- Reaffirmed full-year 2026 net revenue guidance of $173–$183 million.
- Reaffirmed full-year 2026 Adjusted EBITDA guidance of $10–$20 million.
- Settled CINVANTI patent litigation with Baxter Healthcare Corporation.